Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)

Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
55 years - 90 years
All
Phase N/A
23 participants needed
1 Location

Brief description of study

Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD).


ADNI3 is the latest phase of the initiative. It is a non-treatment clinical research study to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.


Data from this research will help determine the best measures for diagnosis and disease monitoring , which will be used to accelerate the testing of therapeutic interventions and ultimately, improve Alzheimer's disease prevention and care.

Detailed description of study

Who can participate?
Individuals who are 55-90, who have a diagnosis of Mild Cognitive Impairment (MCI or Alzheimer's Disease (AD). Who have a reliable study partner who has frequent contact and who can accompanying you to the study visits for the duration on the study and who are willing to participate in repeated imaging and biomarker collection.

What does the study include?
 If you agree and are eligible to participate in the study, you will be asked to come in for:
  • an initial screening visit and baseline visit
  • an annual or biannual follow-up clinic visit

Screening Procedures include:
  • Brain imaging such as MRI and PET/CT scans
  • Memory Testing
  • Physical and Neurological Exam
  • Lumbar Puncture
  • Blood Draw
Before enrolling into the study, the participant and study partner must read, understand, and sign a formal consent, which fully explains the study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: MCI,AD
  • Age: 55 years - 90 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 825666

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center